The Effect of Infliximab on Patients with Ulcerative Colitis in Korea

• Published in: Intestinal research Vol. 12; no. 3; pp. 214 - 220
• Main Authors: Seo, Hyun Il, Park, Dong Il, Kim, Tae Oh, Kim, You Sun, Lee, Suck-Ho, Kim, Ji Won, Kim, Jae Hak, Shin, Jeong Eun
• Format: Journal Article
• Language: English
• Published: Korean Association for the Study of Intestinal Diseases 01-07-2014; 대한장연구학회
• Subjects: Efficacy; Infliximab; Original; Safety; Ulcerative colitis; 내과학
• ISSN: 1598-9100; 2288-1956
• DOI: 10.5217/ir.2014.12.3.214

Background/AimsInfliximab was introduced recently as a rescue therapy for ulcerative colitis (UC) patients refractory to conventional treatments such as therapy with 5-amiono salicylic acids (5-ASA), immune modulators, and corticosteroids. However, there is insufficient data about its efficacy and safety in Korea.MethodsFrom 7 tertiary referral hospitals, 33 patients who were treated with infliximab for moderate to severe (Mayo score 6-12) UC refractory to conventional treatment were recruited to this study. Clinical remission was defined as a total Mayo score of 2 or lower and every subscore less than 2. Partial response was defined as a decrease of Mayo score at least 3 points from baseline.ResultsTwenty-three patients (69.7%) showed clinical remission and 29 patients (87.8%) showed partial response in the observation period. When the remission and non-remission groups were compared in univariate analysis, only a higher total Mayo score at base line (11.0±0.9 vs. 9.9±1.5; P=0.04) was related to remission. The remission maintenance rate decreased with time in the Kaplan-Meier analysis. Two patients experienced re-remission after the first remission followed by aggravation during infliximab treatment. Three patients stopped infliximab treatment owing to adverse events including rhabdomyolysis, pneumonia, and fever of unknown origin.ConclusionsIf there is no choice except surgery for UC patients refractory to conventional treatment, infliximab is an effective and relatively safe treatment option for these patients in Korea.